当前位置：   首页 > 需求大厅

 >  生产研发 

肾近端小管是肾单位的一部分(肾脏的功能部件)，是人体高专属性参与重吸收和排泄各种物质（包括盐和矿物质）的器官，盐和矿物质的重吸收对身体是非常重要的，否则会失去在尿液中。此外，肾近端小管对许多药物的处理也是至关重要的，所谓的外源性物质,来自外面的身体和环境(如许多人造物质,包括潜在的毒素)。然而,没有好的体外模型可以描述和模仿肾近端小管的功能。建立肾近端小管一个有力的模型是非常必要的，特别是在肾近端小管在药物的相互影响方面有至关重要的作用，因为它是会由于药物毒性和药物之间的作用而非常容易受到伤害导致肾脏疾病。在体外开发肾近端小管模型的系统可以帮助填补肾脏疾病研究中药物毒性和药物处理方面的一些空白。 具体看 https://www.innocentive.com/ar/challenge/9933749 The proximal tubule, a part of the kidney nephron (the functional unit of the kidney), has highly specialized properties to do with the salvage and excretion of various compounds, salts and minerals that are very important to the body and would otherwise be lost in the urine. In addition, the proximal tubule is essential for the handling of many drugs and so-called xenobiotics that come from outside the body and from the environment (e.g., many artificial substances, including potential toxins). However, there are no good human models in vitro that can recapitulate and reproduce the function of the proximal tubule. A robust model for the proximal tubule is needed, especially since the proximal tubule has an essential role in drug clearance, because it is highly susceptible to damage in many kidney diseases, and it is also a target for drug-drug interactions and drug toxicity. Development of a proximal tubule model system in vitro could help to address some of the gaps in laboratory models for the study of kidney disease, toxicity, and drug handling. AstraZeneca is seeking innovative approaches to developing a model system of the proximal tubule in vitro. Ideally, the model should incorporate a self-contained microphysiological unit in which biologically appropriate media, fluid flow, and shear stress can be modulated to reproduce the properties of the proximal tubule in vivo and ultimately recapitulate the structural and cellular conditions necessary for integrated proximal tubular function. This is an ideation challenge and only requires a written solution. Source: InnoCentive Challenge ID:   [更多]

基因治疗的概念出现在几十年前,当研究人员推测,人类疾病可以通过精确使用一种技术引入外来DNA来解决遗传缺陷和疾病症状。近年来，基因治疗的进步已经涉足治疗遗传疾病，癌症，神经退行性疾病等各领域。遗传性疾病如色素性视网膜炎等少数眼部疾病的基因也可以如此治疗。公司征集一种在人类眼部组织定性和定量(半)测量体内基因表达的方法。 具体如下https://www.innocentive.com/ar/challenge/9933643 The concept of gene therapy arose decades ago, when researchers postulated that human diseases could be treated by using a technique to introduce foreign DNA to correct genetic defects and disease phenotypes. In recent years, advances in gene therapy have been documented in the treatment of genetic disorders, cancer, and neurodegenerative diseases. Inherited diseases such as retinitis pigmentosa are among a handful of ocular diseases that are amenable to gene therapy. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933643 Challenge Overview The number of clinical trials for gene therapy to treat ocular disorders is on the rise. Inherited diseases such as retinitis pigmentosa among others are thought to be good candidates for targeted treatment. Currently, there is no method in humans to determine the level or geographic location of transgene expression following administration of gene therapy for diseases of the eye, specifically the retina. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 20, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a   [更多]

我们体内以分泌胰岛素来维持胰岛细胞血糖水平和体内平衡。而糖尿病患者的胰岛细胞是缺乏或无效的。没有足够活性的胰岛素，糖尿病患者就无法控制血糖。胰岛移植是一种治疗策略,糖尿病患者需要胰岛素注射来控制他们的疾病，减轻或根除症状。阿斯利康正在寻找一个简单的装置将人类胰岛移植出来，来检测药物的性能。 具体如下网站，https://www.innocentive.com/ar/challenge/9933735 Pancreatic islet beta-cells sense blood sugar levels and secrete insulin to maintain homeostasis. In patients with diabetes, islet beta-cells are either lacking or ineffective. Islet transplantation is a treatment strategy that allows diabetics to reduce or eliminate the need for insulin injections to control their disease. AstraZeneca is searching for a simple device to transplant human islets to facilitate testing of therapeutic agents. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933735 Challenge Overview Diabetes is a disease of the pancreatic islet cells. Of the four cell types, insulin-producing beta-cells are the most abundant. Without adequate levels of insulin, diabetes patients have difficulty controlling their blood sugar. One alternative to self-administration of medicine is islet transplantation. The procedure involves an infusion of isolated donor islets into the patient. If the graft is accepted, these islets will function to regulate blood glucose levels through the production of insulin. AstraZeneca is searching for a simple device for the transplantation and subsequent retrieval of human islets to support in vivo testing of therapeutic agents. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical   [更多]

具体要求：　要求工艺成熟,具有成本优势.   [更多]

我们需要设计自动崩解控制器用于靶向给药。自动崩解控制器，一旦触发，应该可以在温和条件(生理)下使药物分子的释放并激活。这个我们可以参考数量有限的文献中描述“self-immolative”（自动分解或自毁）连接器，但我们提出的自动崩解控制器不是这样的装置。具体链接为https://www.innocentive.com/ar/challenge/9933733，具体如下： Design of A Self-Cleaving Linker For Targeted Drug Delivery TAGS: Physical Sciences, Novel Molecules, Chemistry, Life Sciences, Theoretical-IP Transfer AWARD: $25,000 USD | DEADLINE: 4/27/15 | ACTIVE SOLVERS: 165 | POSTED: 3/26/15 The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of “self-immolative” linkers are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933733 Challenge Overview The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of such “self-immolative” linkers, based upon an elimination to generate a quinone methide, or utilizing a 5 or 6 member ring cyclization, are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property   [更多]

标题：重金求购更昔洛韦标准提高 详细要求： 需求名称：更昔洛韦标准提高 具体要求：招标报价，价格面议 要求时间：请在2015年4月之前 交稿方式：直接点击交稿在线交稿就是了，我会每天过来看的，谢谢各位药智的战友们   [更多]

中文别名： 7-溴-1-环丙基-8-二氟甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸乙酯 英文名称： 3-Quinolinecarboxylicacid, 7-bromo-1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-, ethyl ester; Ethyl7-bromo-1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxoquinoline-3-carboxylate;Ethyl7-bromo-1-cyclopropyl-8-difluoromethoxy-4-oxo-1,4-dihyd... CAS No.： 194805-07-7 EINECS号： 分子式： C16H14 Br F2 N O4   [更多]

技术需求描述：中药材的种植、栽培技术，田间管理及产品收获干燥技术，中药材规范化种植技术（GAP）等。保证中药材能够得到合理的利用，控制中药材种植和使用风险。   [更多]

猎梯医药人才网需求医药专家数名，主要为设备、GMP、生产管理、工程管理、QP等，具有较好的表达能力。   [更多]

【基本信息】 需要 受试者类型 ： 健康受试者 性 别 ： 不限 婚 姻 状 况 ： 不限 适 应 专 业 ： 药物适应症： 胃炎 胃溃疡 招 募 人 数： 90人 试验起止日期 ： 2014-11-08 -- 2015-03-19 报名截止日期 ： 2015-03-01 补 偿 金 ： ￥4000 【项目描述】 《南京医院招试药》 .；时间安排：4天在医院住宿无间隔； 绝对安全；住院当天免费提供一日三餐 空调 热水器 24小时开放 电视 无线网 麻将 扑克 本次药名：右旋兰索拉唑《隶属胃药药》 本次补偿金：4000元， 时间安排：一月九号号早上7点30空腹体检 十一号入住 十五号出组发钱 要求：女生5人 持本人有效身份证 报名电话：18021275657或QQ群 424267082都可以 要求年龄19——29岁，体重大于50公斤，健康值19——24，健康值就是你的体重（按公斤算）除以你的身高（按米算),再除以你的身高（按米算），例如你的身高是1米72，体重是70公斤，70除以1.72再除以1.72等于23.66，你在健康值范围内 【入选标准】 《南京医院招试药》 .；时间安排：4天在医院住宿无间隔； 绝对安全；住院当天免费提供一日三餐 空调 热水器 24小时开放 电视 无线网 麻将 扑克 本次药名：右旋兰索拉唑《隶属胃药药》 本次补偿金：4000元， 时间安排：一月九号号早上7点30空腹体检 十一号入住 十五号出组发钱 要求：女生5人 持本人有效身份证 报名电话：18021275657或QQ群 424267082都可以 要求年龄19——29岁，体重大于50公斤，健康值19——24，健康值就是你的体重（按公斤算）除以你的身高（按米算),再除以你的身高（按米算），例如你的身高是1米72，体重是70公斤，70除以1.72再除以1.72等于23.66，你在健康值范围内 【研究中心列表】 南京 江苏省人民医院 【联系方式】 联系人 ： 施尘 手 机 ： 18021275657   [更多]